|
Post by mindovermatter on Feb 3, 2016 20:15:04 GMT -5
Bankruptcy note. Matt said it would be last resort but that no plans for it. My read on that "no plans" for it is he hopes that negotiation with lenders etc will help buy time but what if those lenders wish not to change the current terms? That BK as last resort is going to come into focus pretty quickly. I know some on here thing the call went well but I do not. Not at all because Matt allowed uncertainty to become a large part of the call. It's why the AH price is tanking and why tomorrow has the makings of a very bad day for the stock. Shall we use the negotiations on the Aug debt as an example? That went well..... Excellent point. Might need to rename the company Botchedkind.
|
|
|
Post by mindovermatter on Feb 3, 2016 18:31:23 GMT -5
Bankruptcy note. Matt said it would be last resort but that no plans for it. My read on that "no plans" for it is he hopes that negotiation with lenders etc will help buy time but what if those lenders wish not to change the current terms? That BK as last resort is going to come into focus pretty quickly. I know some on here thing the call went well but I do not. Not at all because Matt allowed uncertainty to become a large part of the call. It's why the AH price is tanking and why tomorrow has the makings of a very bad day for the stock.
|
|
|
Post by mindovermatter on Feb 3, 2016 18:08:48 GMT -5
Matt kept his word. Better communication and transparency is evident. Sadly no news that's going to move the needle. In fact, I suspect that the bears will find enough negative to drive pps down for awhile. Others I'm sure will have more to say - here's a few highlights: Working with SEC to investigate blatant trading abuses! They (both) are aware and engaged actively. MNKD owns and controls a very significant patent portfolio (more than a thousand!)- actually it's HUGE! God knows what the patents are worth alone. Afrezza will include co-promotion with a partner but will retain all ownership rights to Afrezza No buyouts on the horizon Bankruptcy is not an option "at this time" - it's absolutely a last resort and not even on the radar No good indication of secured financial stability beyond 6 months or so - troubling FDA regulations are hamstringing the company (my words, not his) with respect to what can and cannot be said and used in marketing of Afrezza No time line provided for Intl marketing but it sounds like talks are ongoing in countries that would accept FDA approvals and require little or no addl trials Very impressive TS pipeline strategy with three solid candidates in early development stages. Looking for partners for each of their three early drug programs. Sorry but patents are worthless if you do not have a product employing them that is selling. Case in point. Exubera.
|
|
|
Post by mindovermatter on Feb 3, 2016 7:54:34 GMT -5
Good luck today ! Hope we get something ! I wouldn't get your hopes up. This will be informational but I have a sense that a dose of reality will put the seriousness of the issues surrounding Mannkind in focuse
|
|
|
Post by mindovermatter on Feb 3, 2016 7:47:22 GMT -5
Good luck today ! Hope we get something ! I wouldn't get your hopes up. This will be informational but I have a sense that a dose of reality will put the seriousness of the issues surrounding Mannkind.
|
|
|
Post by mindovermatter on Feb 3, 2016 7:44:26 GMT -5
|
|
|
Post by mindovermatter on Feb 2, 2016 17:02:13 GMT -5
Who said Sanofi is free from liability w/ Mnkd. Read Biodel, Genzyme lawsuits. Read more: mnkd.proboards.com/thread/4834/ajmc-sny-mnkd-breakup-insight?page=2#ixzz3z35G6LbqPfizer, Nektar Reach Exubera Settlement November 13, 2007 Pfizer and Nektar Therapeutics have reached an agreement settling their contractual issues regarding Exubera and Nektar's new inhaled insulin product, which is currently in Phase I. Nektar will receive a one-time payment of $135 million from Pfizer to end all obligations under existing agreements relating to Exubera and the new product. Also, if Nektar finds a new partner, Pfizer will transfer its remaining rights and all economic benefits for Exubera and the new product. This would include the transfer of the Exubera NDA and INDs and all ex-U.S. regulatory filings and applications, continuation of ongoing Exubera clinical trials and certain supply chain transition activities. Jeffrey B. Kindler, chairman and chief executive officer of Pfizer and Howard W. Robin, president and chief executive officer of Nektar issued a joint statement about the settlement, "This agreement demonstrates the industry leadership of Pfizer and the company's desire to work with world-class biotechnology partners like Nektar. The agreement strengthens our relationship and demonstrates our ability to work together to craft a solution that allows Nektar the ability to pursue additional commercial opportunities for the Exubera and its next generation inhaled insulin franchises. Further, we look forward to advancing our joint development of PEGylated human growth hormone therapy to treat short stature and growth problems." - See more at: www.contractpharma.com/contents/view_breaking-news/2007-11-13/pfizer-nektar-reach-exubera-settlement#sthash.pfSObdSy.dpufA fair settlement needs to include $30M EMA MAA, $20M Japan MAA, $25M for qualifying Sanofi's insulin, $200M on-going Pediatric trial, 5-yr/8K PWD lung trial, $30M supply chain transition, $50M breach of min insulin purchase with AMPH, possibly $250M first sale milestone.So, the settlement range is ~ $355M-$605M. This is still pocket change considering that Pfizer sank $2B into Exubera plus $135M settlement. U.S. legal judgement is based on precedence. At min, $355M would extend runway by 2.5 - 3 years. While it would be great to see Mannkind be able to extract something from Sanofi, the Nektar arrangement with PFizer is specific to them and, imo, isn't a very good model to use in regards to Mannkind. The contract with Sanofi is different than the contract Nektar had with Pfizer. I have stated we should soon find out what Sanofi will do as I am sure Sanofi wants to wrap this up sooner rather than later. Sanofi has a lot of bigger problems to deal with at this time.
|
|
|
Post by mindovermatter on Feb 2, 2016 15:14:38 GMT -5
Ok. Ok. I get it. You don't like the site. But it's a positive article! Better then a negative one? Am I missing something? I really just can't win with you people? What you are missing is that it means absolutely nothing. Any of the negative article don't mean anything either. Wall Street has had Mannkind in its cross hairs for years now. The only thing that will matter is when the GS, or ML/BofAs of the world come out saying they are now positive on Mannkind. the only way that happens is when Mannkind finally shows it can sell Afrezza and make MONEY or a deal with nice upfront cash is done for TS. As we know, neither have happened. It is why tomorrow is crucial for Matt to lay out a credible story that Mannkind will prosper.
|
|
|
Post by mindovermatter on Feb 2, 2016 15:06:43 GMT -5
Their ranking is about as influential as mine. The stock won't budge until Wall Street firms get behind it and realize the potential. Wall Street has Mnkd for dead.
|
|
|
Post by mindovermatter on Feb 2, 2016 14:10:17 GMT -5
Where did you find this picture? The version that the ReceptorLife twitter account used the fire was top right, green top left, blue lower right and it was like a desert color bottom left, unfortunately I screen grabbed the 416 torn paper and not the earth pic, but the earth colors did resemble the Microsoft colors just flipped from left to right. I was researching the 416 and found that 416 is Toronto area code and there is a 416 medicinal health clinic. i didn't find or post it. cgiscgis did.
|
|
|
Post by mindovermatter on Feb 2, 2016 11:14:37 GMT -5
They used a version of this; the number 416 references some obscure gospel stuff regarding medicine. This is someone who is having a lot of fun torturing longs. LDS mind trip man!
|
|
|
Post by mindovermatter on Feb 2, 2016 9:30:01 GMT -5
I tweeted this morning that the @receptorlife logo had the Microsoft colors. I just checked my account noticed Receptor blocked me from following them and viewing their twitter content. The account has gone dark. Literally as the pictures are all black.
|
|
|
Post by mindovermatter on Feb 2, 2016 9:15:41 GMT -5
One thing is for certain. Matt will have to explain very clearly how Mannkind affords to stay in business going into the 2nd half of the year as money will run out then. He needs to quickly detail a plan to remain solvent because the life of Mannkind hangs in the balance. Tomorrow will hopefully address a clear picture how that happens. The unsettling truth is that it might be very very bad for shareholders but someone has to be sacrificed for the good of the company. And that is usually shareholders.
|
|
|
Post by mindovermatter on Feb 1, 2016 13:37:23 GMT -5
Are you a diabetic? If not, perhaps there's part of your answer. Beyond that you cannot expect the world to meet what you would believe is a reasonable expectation - you can certainly argue that your expectation is reasonable but results are the only thing that matter - the rest falls into place or doesn't. I love the results I am seeing and though we have yet to encounter the volume to begin even considering a tipping point, it will come - in time. Word of mouth is everything - consumer psycholgy on the other hand varies. Word of mouth hasn't yet worked for Afrezza. Tudiabetes has a new podcast and the two women hosting it made some good points about why Afrezza hasn't taken off in the diabetic community. The one caveat and sad thing about the podcast is both women aren't all that knowledgeable about Afrezza. Neither have tried it and both think there is a 2 unit cartridge available or at least one does while the other one, if she did know there wasn't one, didn't correct the other's wrong information. www.tudiabetes.org/et24/
|
|
|
Post by mindovermatter on Feb 1, 2016 13:11:25 GMT -5
It is why I scratch my head as to why we have seen very little comments from people using Afrezza. After a year, its pretty much the same people who have been discussing their time on Afrezza. I would have thought we'd see many more people comment on their use while on the drug. Maybe I am expecting too much. Most people don't publicize the drugs they are taking. What drugs are you taking and for what condition and what is your real name?........ See? Normally, I'd agree with you but you are misrepresenting my post. There are many PUBLIC online diabetes boards, support groups and people who discuss their diabetes and how they treat themselves. Why do you think I brought it up in the first place? So, in the context of diabetes itself, your comment is quite daft and ignores the reality of what is publicly available in the diabetes community. I'd love to write "SEE?" back to you but its obvious you that you can't.
|
|